

# Research workbook

## 2025

*France*

---

### *Contributors*

Valérie Ulrich, Isabelle Michot, Cristina Díaz Gómez

**2025 National report (2024 data) to the EUDA by the French Reitox National Focal Point**

**Supervision:** Guillaume Airagnes

**Coordination:** Marianna Perebenesiuk

**Contribution to the workbooks**

- 1. *Drug policy:* Cristina Díaz Gómez
- 2. *Legal framework:* Caroline Protais
- 3. *Drugs:* Olivier Le Nézet, Sabrina Cherki, Eric Janssen
- 4. *Prevention:* Carine Mutatayi
- 5. *Treatment:* Sophie Véron, Cindy Feng
- 6. *Best practice:* Valérie Ulrich, Carine Mutatayi
- 7. *Harms and Harm Reduction:* Cindy Feng, Sophie Véron, Eric Janssen
- 8. *Drug market and crime:* Yasmine Salhi
- 9. *Prison:* Caroline Protais, Cindy Feng, Sophie Veron, Lucas Bérard
- 10. *Research:* Valérie Ulrich, Isabelle Michot, Cristina Díaz Gómez

**Proofreading:** Nicolas Prisse, president of the Interministerial Mission for Combating Drugs and Addictive Behaviours, and the project managers of the MILDECA  
Ivana Obradovic, Valérie Ulrich, Stanislas Spilka

**Proofreading (English version):** Anne de l’Eprevier, Marianna Perebenesiuk

**Bibliographic references:** Isabelle Michot

**Legal references:** Anne de l’Eprevier

**Table of contents**

**T0. Summary** ..... 3

**T1. Drug-related research** ..... 4

**T2. Trends (Not applicable for this workbook)** ..... 8

**T3. New developments** ..... 8

**T4. Additional information** ..... 28

**T5. Sources and methodology** ..... 28

## T0. Summary

Please provide an abstract of this workbook (target: 500 words) under the following headings: National profile

In this section please summarise the most relevant information included in the following sections, namely:

- A description of national profiles:
  - main entities financing research on drugs;
  - main research institutions involved in the research on drugs;
  - if applicable, the role of the national drug observatory in the implementation, execution or coordination of drug-related research activities;
  - main national or regional scientific journals publishing drug related research and
  - main drug-related research projects, (planned or ongoing)
- A description of research priorities (if available)
  - drug-related priorities defined in national/regional drug policy;
  - the role of drug-related research in national drug policy documents;
  - new topics emerging in drug-related research in your country (either in governmental or non-governmental research)

### **National profile**

In France, the Ministry of National Higher Education, Research and Innovation (MENESR) designs, coordinates and implements national policy on research and innovation. Two primary academic organisations, the National Centre for Scientific Research (CNRS) and the National Institute for Health and Medical Research (INSERM), cover a wide range of research areas, from neurosciences, through public health and clinical research to social sciences.

The French National Focal Point (OFDT) is the main body involved in drug-related data collection, studies and network development. It collaborates extensively with national and European drug-related research teams. Dissemination of data and research results are also part of its mandate, together with publishing in national and international scientific journals, and promoting the use of research results in practice and policymaking.

The Interministerial Mission for Combating Drugs and Addictive Behaviours (MILDECA) is the central structure close to the Prime Minister responsible for coordinating governmental action in the drugs field. Part of its role is to promote and fund drug-related research. Through its interministerial position and its collaboration with the OFDT and other partners, MILDECA plays a major role in the transfer of knowledge to decision-makers, professionals and citizens in France. MILDECA uses its own appropriations (Finance Act/drugs fund) to support research of a particularly strategic nature for steering public policies on drugs and addictive behaviour

### **New development**

On 9 March 2023, the Government adopted its new [Inter-ministerial Strategy for Mobilisation against Addictive Behaviours](#) (SIMCA) to be deployed over 4 years (2023-2027) (MILDECA 2023).

In line with previous government plans, the development of observation and research on addictions constitutes one of the 10 strategic areas retained in this strategy. The public authorities are reaffirming their desire to base public action on solid knowledge. They are committed to supporting and directing the production of scientific data, which can easily be used by the public authorities.

Government guidelines aim to 1/ consolidate observation systems, 2/ continue to structure research and 3/ promote the evaluation of systems and policies.

Among the research priorities, the strategy stresses the importance of clinical research aimed at developing effective drug treatments, in particular with regard to addictions for which there are no substitute products (cocaine).

At the same time, particular attention is paid to the development of research on the illicit supply of narcotics.

The public authorities also underline their desire to promote evaluative research on subjects that have received little attention such as the quality, effectiveness and efficiency of health and medico-social care as well as penal responses to the use of psychoactive products.

## T1. Drug-related research<sup>1</sup>

The purpose of this section is to

- Describe the organization of drug-related research in your country
- Provide a summary of specific resources on drug-related research available in your country
- Update the available information already provided to the EMCDDA (workbook will be pre-filled).

T1.1. Please update the main drug-related research institutions/associations/bodies (public or private) in your country. Please provide links, also to pages in English, if available.

- Centre National de la Recherche Scientifique (CNRS) : <http://www.cnrs.fr/index.php>
- Conservatoire National des Arts et Métiers (CNAM) : <https://www.cnam.fr/site-fr/>
- École des Hautes Études en Santé Publique (EHESP) : <http://www.ehesp.fr>
- École des Hautes Études en Sciences Sociales (EHESS) : <https://www.ehess.fr>
- France Universités : <https://franceuniversites.fr/en/>
- Fédération Nationale des Observatoires Régionaux de la Santé (FNORS) : <http://www.fnors.org/index.html>
- Fondation Nationale des Sciences Politiques (FNSP) : <https://www.sciencespo.fr/fr/>
- Institut de Recherche pour le Développement (IRD) : <https://www.ird.fr/>
- Institut National de Recherche pour l’agriculture, l’alimentation et l’environnement (INRAE) : <https://www.inrae.fr>
- Institut National de la Santé et de la Recherche Médicale (INSERM) : <https://www.inserm.fr>
- Observatoire Français des Drogues et des Tendances addictives (OFDT) : <https://www.ofdt.fr/>
- Santé publique France (SpF) : <https://www.santepubliquefrance.fr/>
- Drogues, sciences sociales et sociétés [Drugs, social sciences and society], a EHESS/INSERM programme with the support of IReSP : <https://drogueshs.hypotheses.org/>

T1.2. Please update the main institutions/associations/bodies/programmes (public or private) funding drug-related research in your country. Please provide links, also to pages in English, if available.

<sup>1</sup> "Drug-related research involves performing a study on illicit drugs, which may involve a range of disciplines, through the use of scientifically accepted methods and procedures, in order to test a hypothesis or answer a specific question." (EMCDDA, 2012 [Drug-related research in Europe: recent developments and future perspectives](#))

- The Fund for Combating Addiction (FLCA) is the main funding source for research on drugs and addictive behaviours in France. It was created within the *Caisse Nationale de l'Assurance Maladie* [National Health Insurance Fund] by the [law no. 2021-1754 of 23 December 2021](#) on the financing of social security for 2022. It succeeds the "fonds de lutte contre les addictions liées aux substances psychoactives" [Fund for Combating Addiction to psychoactive substances] (set up in 2019 by [law no. 2018-1203 of 22 December 2018](#)), which itself replaced the "fonds de lutte contre le tabac" [Fund for Combating Tobacco] (set up in 2017 by [decree no. 2016-1671 of 5 December 2016](#)). This modified, among other things, the volume and distribution of resources dedicated to research, with a substantial annual sum earmarked to "support knowledge sharing, innovation, applied research and the evaluation of prevention and care actions".
- The Interministerial Mission for Combating Drugs and Addictive Behaviours (MILDECA: <http://www.drogues.gouv.fr/>) is the central structure responsible to the Prime Minister for coordinating governmental action in the drugs field. Part of his role is to promote and fund drug related research. In line with the National Drug Action Plan 2018-2022, the MILDECA supported new annual [calls for proposals](#) and extended collaborations with research organizations/universities and with the ANR. It also promoted clinical research networks and dissemination initiatives towards the scientific community and policy makers. Measure 6 of the national anti-narcotics plan adopted in September 2019 (Ministère de la Justice *et al.* 2019), provides for updated studies analysing the evolution of use and the impact of drug trafficking on the functioning of society in conjunction with the MILDECA "because curbing the influence of drugs in certain regions is complex".
- The Ministry of Higher Education, Research and Innovation (MESRI: <https://www.enseignementsup-recherche.gouv.fr/>) designs, coordinates and implements national policy on research and innovation. A large scope of research areas ranging from neurosciences, through public health and clinical research to social sciences is mainly covered by two major academic operators: the National Centre for Scientific Research (CNRS) and the National Institute for Health and Medical Research (INSERM).
- The French Research Agency (*Agence Nationale de la Recherche* – ANR: <http://www.agence-nationale-recherche.fr/en/project-based-funding-to-advance-french-research/>) is in charge of programming national research and innovation. The agency establishes the thematic priorities of research and allocates the resources. Every year, the agency launches calls for tenders covering a large spectrum of scientific areas.
- The Ministry of Labour, Health, Solidarity and the Family (<https://sante.gouv.fr/>) funds, in specific years, clinical projects on addiction treatment in hospitals (under the programme "*Programme Hospitalier de Recherche Clinique*" - PHRC). It also funds studies on specific populations of drug users, interventions (prevention, treatment, harm reduction) or legal disposition.
- The National Research Agency on AIDS (*Agence Nationale de Recherche sur le Sida* – ANRS: <https://www.anrs.fr/>) and the French Public Health Agency (*Santé publique France*: <https://www.santepubliquefrance.fr/>) implement regular surveys and research projects, notably on the links between injecting drug use and infectious diseases (mainly HIV and HCV). Under the supervision of the MESRI (Ministry of Higher Education, Research and Innovation) and the MSP (Ministry of Health and Prevention), the ANRS also brings together an inter-institutional network of national and international doctors and researchers, patient associations and representatives of civil society, working together to define and implement projects. SPF's research and expertise work on addictions is carried out within the framework of two units of the agency, one being dedicated to infectious diseases and the other devoted to prevention and health promotion.

- The French National Cancer Institute (*Institut national du cancer* – INCa: <http://en.e-cancer.fr/>) is the preeminent health and science agency in charge of cancer control in France, created in 2004. It reports to the ministries for Health and for Research. About half of its budget (€100 million) is allocated to research funding. Each year, the Institute organises more than fifteen competitive calls for proposals in the areas of research, public health, cancer care organisation and patient information.
- The Institute for Public Health Research (*Institut de Recherche en Santé Publique GIS-IreSP*, <http://www.iresp.net/>) helps support and facilitate research into psychoactive substance use and addiction through a funding mechanism composed of calls for research proposals, calls for applications for PhD grants, calls for support actions. It is financed by the Fund for Combating Addiction.
- Regional health agencies (*Agences regionales de santé - ARS*) implement national health policy at local level. The regional roadmaps drawn up for this purpose may include budgets for addiction research projects.
- NGOs and foundations (such as the *Fondation de France*) representing practitioners, users and companies (alcohol suppliers, tobacco industry and pharmaceutical laboratories) also regularly fund surveys and research project in these areas.

T1.3. Please update the list of the main national scientific journals where drug-related research is published in your country. Please provide links, also to pages in English, if available.

Name	Topic	Language	Abstract
Actualités pharmaceutiques <a href="https://www.em-consulte.com/revue/ACTPHA">https://www.em-consulte.com/revue/ACTPHA</a>	Treatment	French	English
Addiction(s) : recherches et pratiques <a href="https://www.federationaddiction.fr/publications/revue/">https://www.federationaddiction.fr/publications/revue/</a>	Treatment	French	French
Adolescence <a href="https://shs.cairn.info/revue-adolescence?lang=fr">https://shs.cairn.info/revue-adolescence?lang=fr</a> <a href="https://shs.cairn.info/journal-adolescence?lang=en">https://shs.cairn.info/journal-adolescence?lang=en</a>	Psychology	French	English
Agora débats/jeunesses <a href="https://shs.cairn.info/revue-agora-debats-jeunesses?lang=fr">https://shs.cairn.info/revue-agora-debats-jeunesses?lang=fr</a> <a href="https://shs.cairn.info/journal-agora-debats-jeunesses?lang=en">https://shs.cairn.info/journal-agora-debats-jeunesses?lang=en</a>	Multidisciplinary	French	English
Alcoologie et Addictologie <a href="https://sfalcoologie.fr/revue/">https://sfalcoologie.fr/revue/</a>	Treatment	French, English	English
Annales Médico-psychologiques, revue psychiatrique <a href="https://www.sciencedirect.com/journal/Annales-Medico-Psychologiques-Revue-Psychiatrique">https://www.sciencedirect.com/journal/Annales-Medico-Psychologiques-Revue-Psychiatrique</a>	Psychiatry	French, English	English
Bulletin de l'Académie Nationale de Médecine <a href="https://www.sciencedirect.com/journal/bulletin-de-l-academie-nationale-de-medecine">https://www.sciencedirect.com/journal/bulletin-de-l-academie-nationale-de-medecine</a>	Public health	French	English
Bulletin Épidémiologique Hebdomadaire <a href="https://www.santepubliquefrance.fr/revues/beh/bulletin-epidemiologique-hebdomadaire">https://www.santepubliquefrance.fr/revues/beh/bulletin-epidemiologique-hebdomadaire</a>	Epidemiology and public health	French	English
Cahiers de la Sécurité et de la Justice <a href="https://www.ihemi.fr/publications/les-cahiers-de-la-securite-et-de-la-justice">https://www.ihemi.fr/publications/les-cahiers-de-la-securite-et-de-la-justice</a>	Sociology and political science	French	English

Le Courrier des Addictions <a href="https://www.edimark.fr/revues/le-courrier-des-addictions">https://www.edimark.fr/revues/le-courrier-des-addictions</a>	Addiction all topics	French	English
Déviance et Société <a href="https://shs.cairn.info/revue-deviance-et-societe">https://shs.cairn.info/revue-deviance-et-societe</a> <a href="https://shs.cairn.info/journal-deviance-et-societe?lang=en">https://shs.cairn.info/journal-deviance-et-societe?lang=en</a>	Sociology and political science	French	English
EchoGéo <a href="https://journals.openedition.org/echogeo/">https://journals.openedition.org/echogeo/</a>	Geopolitics	French	English
L'Encéphale <a href="https://www.sciencedirect.com/journal/lencephale">https://www.sciencedirect.com/journal/lencephale</a>	Treatment	French, English	English
L'Information Psychiatrique <a href="https://www.jle.com/en/revues/ipe/revue.phtml">https://www.jle.com/en/revues/ipe/revue.phtml</a>	Treatment	French, English	English
Médecine des Maladies Métaboliques <a href="https://www.sciencedirect.com/journal/medecine-des-maladies-metaboliques">https://www.sciencedirect.com/journal/medecine-des-maladies-metaboliques</a>	Medicine	French	English
Médecine/Sciences <a href="https://www.medecinesciences.org/fr/">https://www.medecinesciences.org/fr/</a> <a href="https://www.medecinesciences.org/en/">https://www.medecinesciences.org/en/</a>	Medicine	French	English
Neuropsychiatrie de l'Enfance et de l'Adolescence <a href="https://www.sciencedirect.com/journal/neuropsychiatrie-de-lenfance-et-de-ladolescence">https://www.sciencedirect.com/journal/neuropsychiatrie-de-lenfance-et-de-ladolescence</a>	Psychiatry	French, English	English
Politix, revue des sciences sociales du politique <a href="https://shs.cairn.info/revue-politix?lang=fr">https://shs.cairn.info/revue-politix?lang=fr</a> <a href="https://shs.cairn.info/journal-politix?lang=en">https://shs.cairn.info/journal-politix?lang=en</a>	Human and social sciences	French	English
La Presse Médicale <a href="https://www.sciencedirect.com/journal/la-presse-medicale">https://www.sciencedirect.com/journal/la-presse-medicale</a>	Health	French, English	English
Psychotropes, Revue internationale des toxicomanies et des addictions <a href="https://stm.cairn.info/revue-psychotropes?lang=fr">https://stm.cairn.info/revue-psychotropes?lang=fr</a> <a href="https://stm.cairn.info/journal-psychotropes?lang=en">https://stm.cairn.info/journal-psychotropes?lang=en</a>	Treatment	French	English
Revue des Maladies Respiratoires <a href="https://www.sciencedirect.com/journal/revue-des-maladies-respiratoires">https://www.sciencedirect.com/journal/revue-des-maladies-respiratoires</a>	Medicine	French	English
Revue Française des Affaires Sociales <a href="https://shs.cairn.info/revue-francaise-des-affaires-sociales?lang=fr">https://shs.cairn.info/revue-francaise-des-affaires-sociales?lang=fr</a> <a href="https://shs.cairn.info/journal-revue-francaise-des-affaires-sociales?lang=en">https://shs.cairn.info/journal-revue-francaise-des-affaires-sociales?lang=en</a>	Human and social sciences	French	English
Revue Française de Sociologie <a href="https://shs.cairn.info/revue-francaise-de-sociologie?lang=fr">https://shs.cairn.info/revue-francaise-de-sociologie?lang=fr</a> <a href="https://shs.cairn.info/journal-revue-francaise-de-sociologie?lang=en">https://shs.cairn.info/journal-revue-francaise-de-sociologie?lang=en</a>	Sociology	French	English
La Revue de médecine interne <a href="https://www.em-consulte.com/produit/revmed">https://www.em-consulte.com/produit/revmed</a>	Medical Sciences	French, English	English
La Revue du Praticien - Monographie <a href="https://www.larevuedupraticien.fr/numeros">https://www.larevuedupraticien.fr/numeros</a>	Medical Sciences	French	English
Rhizome <a href="https://orspere-samdarra.com/publications/rhizome/">https://orspere-samdarra.com/publications/rhizome/</a>	Mental health and precariousness	French	French
Santé Publique <a href="https://stm.cairn.info/revue-sante-publique?lang=fr">https://stm.cairn.info/revue-sante-publique?lang=fr</a> <a href="https://stm.cairn.info/journal-sante-publique?lang=en">https://stm.cairn.info/journal-sante-publique?lang=en</a>	Epidemiology and public health	French	English

Sciences Sociales et Santé <a href="https://stm.cairn.info/revue-sciences-sociales-et-sante?lang=fr">https://stm.cairn.info/revue-sciences-sociales-et-sante?lang=fr</a> <a href="https://shs.cairn.info/journal-sciences-sociales-et-sante?lang=en">https://shs.cairn.info/journal-sciences-sociales-et-sante?lang=en</a>	Human and social sciences	French, English	English
Sécurité globale <a href="https://shs.cairn.info/revue-securite-globale?lang=fr">https://shs.cairn.info/revue-securite-globale?lang=fr</a>	Sociology and political science	French	French
Sociologie <a href="https://shs.cairn.info/revue-sociologie?lang=fr">https://shs.cairn.info/revue-sociologie?lang=fr</a> <a href="https://shs.cairn.info/journal-sociologie?lang=en">https://shs.cairn.info/journal-sociologie?lang=en</a>	Sociology	French	English
Soins Psychiatrie <a href="https://www.em-consulte.com/revue/SPSY/presentation/soins-psychiatrie">https://www.em-consulte.com/revue/SPSY/presentation/soins-psychiatrie</a>	Psychiatry	French	English
Therapies <a href="https://www.sciencedirect.com/journal/therapies">https://www.sciencedirect.com/journal/therapies</a>	Treatment	French, English	English
Toxicologie Analytique et Clinique <a href="https://www.sciencedirect.com/journal/toxicologie-analytique-et-clinique">https://www.sciencedirect.com/journal/toxicologie-analytique-et-clinique</a>	Toxicology	French, English	English

- T1.4. Please update the list of drug-related research relevant websites/resources you would like us to include in your research country profile. Provide links, also to pages in English, if available.

## T2. Trends (Not applicable for this workbook)

## T3. New developments

The purpose of this section is to provide information on any notable or topical developments observed in drug-related research in your country **since your last report**.

T1 is used to establish the baseline of the topic in your country. Please focus on any new developments here. If information on recent notable developments have been included as part of the baseline information for your country, please make reference to that section here. It is not necessary to repeat the information.

- T3.1. Please update the list of the main drug-related, recent/on-going since your last report studies/research projects in your country. Please provide links, also to pages in English, if available.

If possible, classify each study/research project under one of the following categories:

- (1) Basic biological, neurobiological and behavioural research (including aetiological and addictive behaviour research);
- (2) Population based and clinical epidemiology (including site surveys, ethnographic studies and acute toxicity studies);
- (3) Demand reduction (including prevention, treatment, harm reduction, reintegration and clinical treatment research);
- (4) Supply, supply reduction and crime;
- (5) Drug policy (including laws, economic issues and strategies);
- (6) Other topics.

If it is not possible to identify the main drug-related on-going studies/research projects in your country, please provide a list of the most relevant current bibliographic references.

Since 2022, the scope of public research funding has been extended to so-called substance-free addictions (screens, gambling and video games) by Article 84 of [Law no. 2021-1754 of 23 December 2021](#) relating to the Social Security financing for 2022. This expansion aims to respond to the concerning reports of problematic uses observed in recent years, mainly among adolescents and young adults.

The information currently collated concerning the efforts devoted to research is set out below.

In 2024, the FLCA financed 32 research projects supported by INCa (National Cancer Institute) and IReSP (Institute for Public Health Research) in many disciplines (neurosciences, epidemiology, public health, economics, social sciences, etc.) for an amount of €9.7 million. Of these 32 projects, 14 require a preliminary study or the prior structuring of a research partnership. This is in addition to funding for 12 doctoral students and support for 5 early-career researchers and 6 research networks.

The following were funded in 2024, among others: a project led by the Committee for the Study and Information on Drugs and Addictions on the effectiveness of vaped cannabidiol in cannabis use disorder; a project by Université Paris Cité on identifying factors of methadone treatment failure; a study conducted by the Centre Hospitalier Le Vinatier on the impact of cocaine addiction on sleep. More broadly, diverse themes and substances were studied in the 2024 projects, with a focus on addiction mechanisms, behavioural addictions and polydrug use; however, tobacco remained the main substance studied (alone or in polydrug use, over one-third of projects) with issues relating to consumption trajectories, withdrawal and prevention.

In 2024, IRESP and INCA also organised a scientific symposium entitled "Addictions and inequalities: public health research perspectives"; and IRESP and CNAM organised a seminar on "Harm reduction".

Moreover, improving knowledge of the illicit supply of narcotics is among the priorities of the National Action Plan for Drugs (Ministère de la Justice *et al.* 2019) jointly headed by the Ministry of Justice, the Ministry of the Interior and the Ministry of Public Accounts. On this specific research area, the MILDECA funded 7 research projects for a total amount of €451 000 in 2024. MILDECA notably funded:

- activities structuring therapeutic research assisted by psychedelic substances led by the psychedelic section of the French Association of Biological Psychiatry and Neuropsychopharmacology;
- a collective INSERM expert report on cocaine with co-funding from the Ministry of Health;
- a study to evaluate the transferability to France of a prevention programme from the English-speaking world to prevent sexual and gender-based violence associated with psychoactive substance use.

MILDECA also launched a call for research in 2024 as part of the PIRALAD programme (Interministerial Applied Research Programme to Combat Drugs) with a 2024 budget of €538 000. This programme funded 5 new research projects in 2024:

- a sociological study on cocaine trafficking in French Guiana;
- a study on the links between drug trafficking and socio-economic conditions;
- a study on the impact of the heroin shortage in France;
- an extension of a study selected in 2023 for a better understanding of cocaine trafficking affecting the French overseas territories and mainland France;
- an estimate of the illicit drug markets in France in 2023 and their trends.

Moreover, at the beginning of 2025, the MILDECA is organising and funding (up to €80,000), together with the Urban School of Sciences Po, a series of unprecedented conferences on the illicit supply of narcotics and its urban challenges.

Since its creation in 2019, the FLCA has funded specific OFDT research projects.

All of these projects are taking place over several years. In 2024, the amount paid for the continuation, completion or launch of multi-annual research projects supported by the FLCA amounted to €1 319 433.

The following studies were completed in 2024 :

- TABATRAJ (Trajectories of tobacco use and cessation), a qualitative survey aimed at describing smoking careers and experiences with smoking.
- ESSPRI 2 (Survey on health and substances in prison), aiming to better assess the consumption of inmates.
- TUPSALCO (Trajectories of use and treatment pathways: the differing perspectives of professionals and alcohol users), a survey aimed at putting into perspective the trajectories of consumption and the provision of care offered to patients seen in withdrawal, aftercare or primary care settings.
- NOVURC (New faces of cannabis users), a survey aimed at describing and understanding the practices of adult (26-64 years old) regular cannabis users, their history of use, trajectories and lifestyles.
- EROPP (Survey on representations, opinions and perceptions regarding psychoactive drugs) has two main objectives: 1/ to measure changes in the French population's opinions of psychoactive substances and their users over the past 25 years, and 2/ to document social representations of issues currently being debated in the public arena (legalization of cannabis, perception of risks associated with alcohol, tobacco and cannabis consumption, legislation on various psychoactive substances, etc.). The 2024 survey will also include data on the estimated prevalences of illicit drug use in the French general population, which has not been available since 2017.

The projects for 2024 are:

- CIPPAL (International Comparison of Public Policies for Controlling the Attractiveness and Accessibility of Alcohol) a survey aimed at drawing up an inventory of the legislation and conditions of access to the supply of alcohol.
- OUDOM (Observations of drug use in the French overseas departments and territories), aiming to 1/ deploy the OFDT's SINTES network in collaboration with actors in the field and laboratories and 2/ conduct qualitative fieldwork on the use and supply of illicit psychoactive substances.

The new actions funded to the amount of €3 684 061 for the year 2024 for the period 2024-2027 were:

- PSPJ (*Sports betting and problematic behaviours among young people*), a qualitative study aimed at better understanding the intrinsic factors and motivations and the environmental incentives for sports betting practices among young adults and adolescents (minors) in France, in light of the trajectories and strategies of engagement in gambling.
- ACCES 2025 (*Representative analysis of the profiles and care pathways of CAARUD users*) aiming to deploy a nationally-representative quantitative survey system among CAARUD users to analyse usage practices and clinical profiles of users.
- VIXAL (*Sexual violence and alcohol consumption*), survey on the links between alcohol consumption and sexual violence using a mixed-methods approach.

- EROPP 2026 (*Survey on representations, opinions and perceptions regarding psychoactive drugs*), enabling the regular production of estimates of levels of drug use and gambling practices and to monitor their trends.
- ESSPRI 3 (*Survey on health and substances in prison*) for the assessment of consumption among detainees in order to provide regular prevalence data on the use of psychoactive substances in detention among adult male and female prisoners incarcerated in France.
- TREND/SINTES (*Structuring and strengthening of the Emerging Trends and New Drugs-TREND/National Identification System for Toxics and Substances-SINTES scheme*) contributing to health monitoring at national and European level.

The total number of scientific publications on addiction published in 2024 up to the first quarter of 2025 equals 229, of which:

- Publications on addiction/addictology: 30
- Publications on cannabis: 31
- Publications on chemsex: 13
- Publications on cocaine/crack cocaine: 29
- Publications on opioids: 19
- Publications on NPS : 21
- Publications on nitrous oxide: 9
- Publications on several products: 70
- Publications on other substances: 7

## **Bibliography 2024-1<sup>st</sup> quarter 2025**

### **(1) Basic biological, neurobiological and behavioural research (including aetiological and addictive behaviour research) = 52 articles**

Aknouche, F., Trebuchet, C., Fargeot, K., Kormazyigit, F., Thion, L., Maruejouis, C. *et al.* (2024). Window of detection of cocaine-related alkaloids in oral fluid collected with the FloqSwab™ after coca tea consumption. Journal of Analytical Toxicology 48 (5) 388-392, 10.1093/jat/bkad093.

Alawoè, C., Chapet, N., Roubille, F., Peyrière, H. and Eiden, C. (2024). Insuffisance cardiaque et cocaïne : revue systématique (in French only). Le Courrier des Addictions 26 (3) 17-25.

Al-Soufi, L., Hindley, G., Rødevand, L., Shadrin, A.A., Jaholkowski, P., Fominykh, V. *et al.* (2025) Polygenic overlap of substance use behaviors and disorders with externalizing and internalizing problems independent of genetic correlations. Psychol Med 55 e100, 10.1017/s0033291725000108.

Aouichi, L.L., Pape, E., Jouzeau, J.Y., Gibaja, V., Aubin-Beale, E., Kolodziej, A. *et al.* (2025) Detection of ketamine in the oral fluid of drivers in northeastern France during the years 2020-2023. Fundam Clin Pharmacol 39 (2) e13060, 10.1111/fcp.13060.

Aragón-Daud, A., Oberti De Luca, S.M., Schurmann Vignaga, S., Prado, P., Figueras, R., Lizaso, L. *et al.* (2024) Attentional ERPs in consumers of smoked and insufflated cocaine associated with neuropsychological performance. Drug and Alcohol Dependence 259 111288, 10.1016/j.drugalcdep.2024.111288.

- Austin-Zimmerman, I., Spinazzola, E., Quattrone, D., Wu-Choi, B., Trotta, G., Li, Z. *et al.* (2024). The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies. Psychol Med 54 (15) 1-13, 10.1017/s0033291724002058.
- Ávila-Gámiz, F., Pérez-Cano, A.M., Pérez-Berlanga, J.M., Zambrana-Infantes, E.N., Mañas-Padilla, M.C., Gil-Rodríguez, S. *et al.* (2025) Sequential physical and cognitive training disrupts cocaine-context associations via multi-level stimulation of adult hippocampal neurogenesis. Progress in Neuro-Psychopharmacology and Biological Psychiatry 136 111148, 10.1016/j.pnpbp.2024.111148.
- Badri, B., Bildstein, F. and Menager, P. (2024). A rare discovery of acute eosinophilic pneumonia associated with intensive cannabis use: Case report. Radiology Case Reports 19 (12) 5766-5769, 10.1016/j.radcr.2024.08.052.
- Barrera-Conde, M., Ramon-Duaso, C., González-Parra, J.A., Veza-Estevez, E., Chevalayre, V., Piskorowski, R.A. *et al.* (2024) Adolescent cannabinoid exposure rescues phencyclidine-induced social deficits through modulation of CA2 transmission. Prog Neurobiol 240 102652, 10.1016/j.pneurobio.2024.102652.
- Berikishvili, T. and Gana, K. (2024). Conscience intéroceptive, croyances métacognitives et spécificités liées au sexe : vers un modèle explicatif du craving [Interoceptive awareness, metacognitive beliefs and sex specificities: towards an explanatory model of craving] (with English abstract). Le Courrier des Addictions 26 (3) 11-16.
- Bernat, N., Campbell, R., Nam, H., Basu, M., Odesser, T., Elyasaf, G. *et al.* (2024) Multimodal interrogation of ventral pallidum projections reveals projection-specific signatures and effects on cocaine reward. J Neurosci 44 (18) e1469232024, 10.1523/jneurosci.1469-23.2024.
- Billaux, P., Segobin, S., Maillard, A., Bloch, V., Delmaire, C., Cabé, N. *et al.* (2024) Let's focus on the insula in addiction: A refined anatomical exploration of insula in severe alcohol and cocaine use disorders. Eur Psychiatry 67 (1) e75, 10.1192/j.eurpsy.2024.1784.
- Blanc, J.V. (2024). Le chemsex en psychiatrie : des effets systémiques ? [Chemsex in psychiatry: Systemic effects?] (with English abstract). Psychotropes 30 (2-3) 137-149.
- Charles, A.L., Giannini, M., Meyer, A., Charloux, A., Talha, S., Vogel, T. *et al.* (2024) Cannabis (THC) Aggravates the Deleterious Effects of Alcohol (EtOH) on Skeletal Muscles' Mitochondrial Respiration: Modulation by Age and Metabolic Phenotypes. Biology (Basel) 13 (12) 1080, 10.3390/biology13121080.
- Chirokoff, V., Berthoz, S., Fatseas, M., Misdrahi, D., Dupuy, M., Abdallah, M. *et al.* (2024) Identifying the role of (dis)inhibition in the vicious cycle of substance use through ecological momentary assessment and resting-state fMRI. Transl Psychiatry 14 260, 10.1038/s41398-024-02949-1.
- Chirokoff, V., Pohl, K.M., Berthoz, S., Fatseas, M., Misdrahi, D., Serre, F. *et al.* (2024) Multi-level prediction of substance use: Interaction of white matter integrity, resting-state connectivity and inhibitory control measured repeatedly in every-day life. Addict Biol 29 (5) e13400, 10.1111/adb.13400.
- Chrétienneau, C., Spindola, L.M., Vorspan, F., Lagerberg, T.V., Marie-Claire, C., Bellivier, F. *et al.* (2024) An epigenetic candidate-gene association study of parental styles in suicide attempters with substance use disorders. Addict Biol 29 (4) e13392, 10.1111/adb.13392.
- Costentin, J. (2024). Outre ses effets aigus, le cannabis/THC par des modifications épigénétiques peut affecter ses consommateurs et leur progéniture [In addition to its acute effects, cannabis/THC induces epigenetic modifications, which can affect its consumers and their offspring] (with English abstract). Bulletin de l'Académie Nationale de Médecine 208 (4) 459-465, 10.1016/j.banm.2024.02.009.

- de Guglielmo, G., Carrette, L., Kallupi, M., Brennan, M., Boomhower, B., Maturin, L. *et al.* (2024) Large-scale characterization of cocaine addiction-like behaviors reveals that escalation of intake, aversion-resistant responding, and breaking-points are highly correlated measures of the same construct. *Elife* 12, 10.7554/eLife.90422.
- Diomande, M., Gandolfo, P., Hari, J.R., Laggiard, E., Djenidi, H., Costedoat, C. *et al.* (2025). Une méthode d'avenir. Le tartre dentaire comme témoin de la consommation de drogues (in French only). *Médecine/Sciences* 41 (1) 100-102.
- Dogruer Erkok, S., Gallois, R., Leegwater, L., Gonzalez, P.C., van Asten, A. and McCord, B. (2024) Combining surface-enhanced Raman spectroscopy (SERS) and paper spray mass spectrometry (PS-MS) for illicit drug detection. *Talanta* 278 126414, 10.1016/j.talanta.2024.126414.
- Drevin, G., Pena-Martin, M., Bauduin, A., Baudriller, A., Briet, M. and Abbara, C. (2024) Pharmacogenomics of 3,4-Methylenedioxymethamphetamine (MDMA): A Narrative Review of the Literature. *Pharmaceutics* 16 (8) 1091, 10.3390/pharmaceutics16081091.
- Engeln, M. and Ahmed, S.H. (2024) The multiple faces of footshock punishment in animal research on addiction. *Neurobiology of Learning and Memory* 213 107955, 10.1016/j.nlm.2024.107955.
- Engeln, M. and Ahmed, S.H. (2025). Remission from addiction: erasing the wrong circuits or making new ones? *Nat Rev Neurosci* 26 115-130, 10.1038/s41583-024-00886-y.
- Estudillo-Romero, A., Migliaccio, R., Batrancourt, B., Jannin, P. and Baxter, J.S.H. (2024) Non-local diffusion-based biomarkers in patients with cocaine use disorder. *Neuroimage: Reports* 4 (2) 100202, 10.1016/j.nirp.2024.100202.
- Feliu, C., Hattat, E., Tholance, Y., Hodin, S., Pipet, J., Panther, T. *et al.* (2025) Investigating 3-CMC metabolism: Insights from liver microsomes and postmortem biological matrix. *Forensic Science International* 367 112364, 10.1016/j.forsciint.2025.112364.
- Gong, W.K., Li, X., Wang, L., Yang, Q., Tiran-Cappello, A., Liang, Z. *et al.* (2025) Prefrontal FGF1 signaling is required for accumbal deep brain stimulation treatment of addiction. *Adv Sci (Weinh)* 12 (16) e2413370, 10.1002/advs.202413370.
- Grandry, A. (2024). L'addiction, pathologie du choix [Addiction, a pathology of choice] (with English abstract). *Gestalt* (62) 15-30, 10.3917/gest.062.0015.
- Improvitato, P., Trouillet, R., Schuldiner, S., Luquiens, A., Hamonnière, T., Donnadiou, H. *et al.* (2024) Role of worry in addiction: Implication of metacognitive beliefs and type 2 worry. *Clinical Psychology and Psychotherapy* 31 (5) e3048, 10.1002/cpp.3048.
- Jeanblanc, J., Bordy, R., Fouquet, G., Jeanblanc, V. and Naassila, M. (2024). Psilocybin reduces alcohol self-administration via selective left nucleus accumbens activation in rats. *Brain* 147 (11) 3780-3788, 10.1093/brain/awae136.
- Jousselin, E., Zarrouk, E., Griffeuille, P., Dulaurent, S., El Balkhi, S. and Saint-Marcoux, F. (2025) Probe electrospray ionization coupled to a quadrupole time-Of-flight: A feasibility study for the detection of cocaine and its derivatives in oral fluid. *J Pharm Biomed Anal* 254 116568, 10.1016/j.jpba.2024.116568.
- Kintz, P., Ameline, A., Gheddar, L., Pichini, S., Mazoyer, C., Teston, K. *et al.* (2024). Testing for protonitazene in human hair using LC-MS-MS. *Journal of Analytical Toxicology* 48 (8) 630-635, 10.1093/jat/bkae050.
- Lacroix, C., Guilhaumou, R., Micallef, J. and Blin, O. (2024). Cannabidiol and pharmacokinetics drug-drug interactions: Pharmacological toolbox. *Therapies* 79 (3) 351-363.

- Lehoux, T., Capobianco, A., Lacoste, J., Rollier, S., Mopsus, Y., Melgire, M. *et al.* (2024) Virtual reality cue-exposure therapy in reducing cocaine craving: the Promoting Innovative COgnitive behavioral therapy for Cocaine use disorder (PICOC) study protocol for a randomized controlled trial. Trials 25 421, 10.1186/s13063-024-08275-7.
- Lehoux, T., Porche, C.N., Capobianco, A., Gervilla, M., Lecuyer, F., Anthouard, J. *et al.* (2024) Towards virtual reality exposure therapy for cocaine use disorder: A feasibility study of inducing cocaine craving through virtual reality. Addictive Behaviors Reports 19 100549, 10.1016/j.abrep.2024.100549.
- Lenoir, M., Engeln, M., Navailles, S., Girardeau, P. and Ahmed, S.H. (2024). A large-scale c-Fos brain mapping study on extinction of cocaine-primed reinstatement. Neuropsychopharmacology 49 1459-1467, 10.1038/s41386-024-01867-6.
- Lichenstein, S.D., Kiluk, B.D., Potenza, M.N., Garavan, H., Chararani, B., Banaschewski, T. *et al.* (2025) Identification and external validation of a problem cannabis risk network. Biol Psychiatry, 10.1016/j.biopsych.2025.01.022.
- Makhdoom, H.S., Afzal, S., Sultana, K., Shah, S.N.H., Mujahid, M., Hassan, Z.U. *et al.* (2024). SPE-UHPLC-ESI-MS/MS Analysis of Cocaine and Its Metabolites in Conventional and Alternative Biological Specimens: Application to Real Samples. ACS Omega 9 (22) 23355-23363, 10.1021/acsomega.3c09669.
- Mense, C., Romao, V., Silvestri, F. and Lan, R. (2024) Limits of prosthetic rehabilitation of cocaine-induced midline destructive lesions: Time to change the paradigm. The Journal of Prosthetic Dentistry, 10.1016/j.prosdent.2024.09.023.
- Mongrédien, R., Anesio, A., Fernandes, G.J.D., Eagle, A.L., Maldera, S., Pham, C. *et al.* (2025) Astrocytes control cocaine-induced synaptic plasticity and reward through the matricellular protein hevin. Biol Psychiatry, 10.1016/j.biopsych.2025.02.904.
- Nadal-Gratacós, N., Mata, S., Puigseslloses, P., De Macedo, M., Lardeux, V., Pain, S. *et al.* (2025) Unveiling the potential abuse liability of  $\alpha$ -D2PV: A novel  $\alpha$ -carbon phenyl-substituted synthetic cathinone. Neuropharmacology 272 110425, 10.1016/j.neuropharm.2025.110425.
- Pelletier, R., Le Daré, B., Kerforne, T., Parvedy, N.P., Lemaitre, F., Tron, C. *et al.* (2025) Cathinone metabolism and biliary excretion in an ex-vivo pig liver model: Example of 4-Cl-PVP and eutylone. Food Chem Toxicol 196 115217, 10.1016/j.fct.2024.115217.
- Quenardelle, V., Charles, A.L., Charloux, A., Raul, J.S., Wolff, V. and Geny, B. (2025) Young Age and Concomitant Cannabis (THC) and Ethanol (EtOH) Exposure Enhances Rat Brain Damage Through Decreased Cerebral Mitochondrial Respiration. Molecules 30 (4), 10.3390/molecules30040918.
- Ravit, M. (2024). L'addiction : un opérateur paradoxal [Addiction: a paradoxical operator] (with English abstract). Adolescence 42 (1) 153-165, 10.3917/ado.113.0153.
- Romeo, B., Kervadec, E., Fauvel, B., Strika-Bruneau, L., Amirouche, A., Verroust, V. *et al.* (2025) Exploring factors associated with the intensity of a mystical experience following naturalistic psychedelic use: A retrospective survey. Prog Neuropsychopharmacol Biol Psychiatry 111300, 10.1016/j.pnpbp.2025.111300.
- Saint-Jour, E., Allichon, M.C., Andrianarivelo, A., Montalban, E., Martin, C., Huet, L. *et al.* (2025) Nuclear calcium signaling in D1 receptor-expressing neurons of the nucleus accumbens regulates molecular, cellular and behavioral adaptations to cocaine. Biol Psychiatry, 10.1016/j.biopsych.2025.01.013.
- Shadili, G., Belbeze, J., Votadoro, P., Essadek, A., Robin, M., Corcos, M. *et al.* (2024). Freud et la cocaïne (in French only). L'Information Psychiatrique 100 (9) 747-753, 10.1684/ipe.2024.2802.

Solinas, M. and Melis, M. (2024) Developmental exposure to cannabis compromises dopamine system function and behavior. Current Opinion in Behavioral Sciences 59 101442, 10.1016/j.cobeha.2024.101442.

Terenzi, D., Simon, N., Gachomba, M.J.M., de Peretti, J.L., Nazarian, B., Sein, J. *et al.* (2024). Social context and drug cues modulate inhibitory control in cocaine addiction: involvement of the STN evidenced through functional MRI. Mol Psychiatry 29 3742-3751, 10.1038/s41380-024-02637-y.

Thiebot, P., Magny, R., Martins, P., Houze, P., Bloch, V., Vorspan, F. *et al.* (2025). Quantitative analysis of cannabinoids and metabolites in oral fluid by volumetric absorptive microsampling combined with UHPLC-HRMS. Anal Bioanal Chem 417 (2) 345-360, 10.1007/s00216-024-05651-9.

Vadas, E., López-Gamero, A.J., Vargas, A., Rodríguez-Pozo, M., Rivera, P., Decara, J. *et al.* (2025) Region-Specific Impact of Repeated Synthetic Cannabinoid Exposure and Withdrawal on Endocannabinoid Signaling, Gliosis, and Inflammatory Markers in the Prefrontal Cortex and Hippocampus. Biomolecules 15 (3), 10.3390/biom15030417.

Vergriete, D. (2024). Traverser les frontières de l'addiction. Journal de l'hypnose et de la santé intégrative (28) 75-84, 10.3917/jhsi.028.0075.

## **(2) Population based and clinical epidemiology**

**(including site surveys, ethnographic studies and acute toxicity studies) = 89 articles**

Anwar, I., Faye, A., Donadille, C., Briand Madrid, L., Lalanne, L., Jauffret-Roustide, M. *et al.* (2025) Gender-based factors associated with hepatitis C testing in people who inject drugs: results from the French COSINUS cohort. BMJ Open 15 (3) e091707, 10.1136/bmjopen-2024-091707.

Barré, T., Lahaie, E., Di Beo, V., Carrieri, P., Andler, R., Nguyen-Thanh, V. *et al.* (2024). Cannabidiol use in France in 2022: Results from a nationwide representative sample of adults. Drug and Alcohol Review 43 (5) 1294-1304, 10.1111/dar.13842.

Barré, T., Lahaie, E., Di Beo, V., Carrieri, P., Andler, R., Nguyen-Thanh, V. *et al.* (2025). Recreational nitrous oxide use in France in 2022: Results from a nationwide representative sample of adults. Drug and Alcohol Review 44 (4) 1182-1193.

Bastien, A. (2024). Les risques de troubles d'usage de substances et de dépression chez les anciens sportifs de haut niveau (with English abstract). Le Courrier des Addictions 26 (2) 18-21.

Bastien, M., Lopez, F., Chappard, P. and Roux, P. (2024). L'utilisation du cannabis dans la gestion des consommations d'autres substances psychoactives. Une enquête par questionnaire auprès de personnes utilisatrices de cannabis en France [Using cannabis to manage consumption of other psychoactive substances: A questionnaire survey of people who use cannabis in France] (with English abstract). Psychotropes 30 (2-3) 171-197.

Bastien, M., Mezaache, S., Donadille, C., Martin, V., Appel, L., Lebrun, M. *et al.* (2024). Exclusive therapeutic use of cannabis in a large sample of daily cannabis users in France: A cross-sectional survey. Journal of Psychoactive Drugs 56 (3) 353-363, 10.1080/02791072.2023.2224313.

Batisse, A., Chaouachi, L., Thiery, J., Roussin, A., Chevalier, C., Caous, A.S. *et al.* (2024). Pratique du chemsex en France : actualisation des données d'addictovigilance [Chemsex practice in France: Updating addictovigilance data] (with English abstract). Psychotropes 30 (2-3) 37-52.

Ben Farhat, J., Hessamfar, M., Neau, D., Farbos, S., Lazaro, E., Duffau, P. *et al.* (2025). Exposure to COVID-19 Pandemic-Related Stressors and Their Association With Distress, Psychological

Growth and Drug Use in People With HIV in Nouvelle Aquitaine, France (ANRS CO3 AQUIVIH-NA Cohort-QuAliv-QuAlivCOV Study). AIDS Behav 29 1118-1131.

Ben Lakhdar, C., Massin, S., Délégation Régionale de « Nous Aussi » and UNAPEI Hauts-De-France (2024). Le Thermomètre de la santé : usages de tabac, d'alcool et de cannabis chez les personnes en situation de handicap intellectuel (with English abstract). Alcoologie et Addictologie 44 (2) 14-22.

Besnier, M., Delouche, M., Birault, F. and Lebonheur, L. (2025). Is buprenorphine maternal dose associated with neonatal opioid withdrawal syndrome severity? American Journal on Addictions 34 (1) 15-20, 10.1111/ajad.13652.

Bezo, A., Benyamina, A., Coscas, S. and Karila, L. (2025). Expérimentations d'usage de substances psychoactives et pratiques addictives chez les jeunes adultes [Experiments with psychoactive substance use and addictive behaviors among young adults] (with English abstract). Neuropsychiatrie de l'Enfance et de l'Adolescence 73 (3) 163-169.

Blanc, J.V., Burdairon, J.D., Malandain, L., Ferreri, F., Mouchabac, S. and Adrien, V. (2024). Attachment and mental health of men having sex with men engaging in chemsex: Is substance abuse only the tip of the iceberg? Journal of Homosexuality 71 (12) 2875-2894, 10.1080/00918369.2023.2266086.

Blanc, J.V. (2025). Chemsex : une pratique qui continue de s'étendre [Chemsex: a growing and evolving practice] (with English abstract). La Revue du Praticien - Monographie 75 (1) 75-79.

Bond, B.W., Duric, B., Spinazzola, E., Trotta, G., Chesney, E., Li, Z. *et al.* (2025). Cannabis Use Cessation and the Risk of Psychotic Disorders: A Case-Control Analysis from the First Episode Case-Control EU-GEI WP2 Study ; L'arrêt de l'utilisation du cannabis et le risque de troubles psychotiques: Une analyse cas-témoins tirée de l'étude cas-témoins EU-GEI WP2 centrée sur les premiers épisodes psychotiques. Can J Psychiatry 70 (3) 182-193.

Bouali, N., Benmansour, O., El Bèze, N., Trimaille, A., Bouleti, C., Brette, J.B. *et al.* (2025). Psychoactive substance use in elderly patients: Insights from the addiction in intensive cardiac care units (ADDICT-ICCU) study. Arch Cardiovasc Dis 118 (6-7) 356-364, 10.1016/j.acvd.2025.02.007.

Brink, V., Andleeb, H., Gayer-Anderson, C., Arango, C., Arrojo, M., Berardi, D. *et al.* (2024). The role of social deprivation and cannabis use in explaining variation in the incidence of psychotic disorders: Findings from the EU-GEI Study. Schizophr Bull 50 (5) 1039-1049, 10.1093/schbul/sbae072.

Cabelguen, C., Begnaud, A. and Grall-Bronnec, M. (2024). TDAH et addictions : fardeau ou levier thérapeutique ? [ADHD and addictions: Burden or therapeutic lever?] (with English abstract). La Presse Médicale Formation 5 (6) 417-426.

Carton, L. and Ménard, O. (2024). TDAH et addictions (in French only). Santé Mentale (292).

Cassen, M. (2024). Maternité et addictions : une revue de la littérature [Maternity and addiction: a literature review] (with English abstract). Devenir 36 (2) 140-163, 10.3917/dev.242.0140.

Chaaban, S., Istvan, M., Schreck, B., Laigo, P., Rousselet, M., Grall-Bronnec, M. *et al.* (2024) Cannabis use and dependence among festival attendees: results from the French OCTOPUS survey. BMC Public Health 24 992, 10.1186/s12889-024-18496-9.

Cotier, P., Mayer, C., Etting, I., Lorin de la Grandmaison, G. and Alvarez, J.C. (2023). Evaluation of the cardiovascular risk induced by cannabis use from a series of 43 autopsy cases. Int J Legal Med 137 (6) 1725-1733, 10.1007/s00414-023-03079-x.

Czerwiec, A., Chevallier, C., Grenet, G., Patat, A.M., de Souza, S., Lichtfouse, J. *et al.* (2024). Exposure to ammonia solution due to substance use: a retrospective study from the French poison centres database (2009-2018). Clinical Toxicology 62 (2) 107-111, 10.1080/15563650.2024.2313088.

- Daveluy, A., Perino, J., Gibaja, V., Le Boisselier, R., Batische, A., Miremont-Salamé, G. *et al.* (2025). From regional signal to alert in addictovigilance. Therapies 80 (2) 213-222.
- Dawudi, Y., Azoyan, L., Broucker, T.D.E., Gendre, T., Miloudi, A., Echaniz-Laguna, A. *et al.* (2024). Marked increase in severe neurological disorders after nitrous oxide abuse: a retrospective study in the Greater Paris area. J Neurol 271 (6) 3340-3346, 10.1007/s00415-024-12264-w.
- de Ternay, J., Nohales, L., Fort, E., Pelloux, S., Coste, C., Leblanc, P. *et al.* (2024). Impact of working conditions and other determinants on the risk of substance misuse among healthcare residents: Results of a cross-sectional study. European Addiction Research 30 (6) 390-401, 10.1159/000542592.
- Delcroix-Gomez, C. (2024). Addictions féminines et éducation thérapeutique [Female addictions and therapeutic education] (with English abstract). Sages-Femmes 23 (3) 10-13.
- Dempster, E.L., Wong, C.C.Y., Burrage, J., Hannon, E., Quattrone, D., Trotta, G. *et al.* (2025). Methylomic signature of current cannabis use in two first-episode psychosis cohorts. Mol Psychiatry 30 1277-1286, 10.1038/s41380-024-02689-0.
- Derne, A.S., Jouzeau, J.Y., Pape, E., Kolodziej, A., Gibaja, V., Marchand, E. *et al.* (2024). Emerging detection of hexahydrocannabinol in driver saliva: Preliminary data. European Addiction Research 30 (6) 402-407, 10.1159/000541760.
- Descœur, J., Eiden, C., Rebillard, Q., Laplace, K., Peyrière, H., Martrille, L. *et al.* (2024). La pratique du Chemsex comme cause de décès : à propos d'une série de cas [Chemsex practice as a cause of death: About a case series] (with English abstract). Toxicologie Analytique et Clinique 36 (2) 186-192, 10.1016/j.toxac.2023.09.010.
- Djoba Siawaya, J.F., Minto'o Rogombe, S., Diawara, M., Avome Houechenou, R.M., Efire Emagha, N.S., Andrews, Z. *et al.* (2024) Survey of the risk behaviors and mental health of adolescents in Gabon risky behaviors and vulnerability of adolescent Africans. Commun Med (Lond) 4 (1) 229, 10.1038/s43856-024-00615-7.
- D'Ottavi, M., Scialabba, I., Huong, D.T., Giang, H.T., Khue, P.M., Vinh, V.H. *et al.* (2025). High prevalence and incidence of HSV-2 among people who inject drugs in Hai Phong, Vietnam, and risk factors associated with seroconversion. European Journal of Clinical Microbiology & Infectious Diseases 44 1119-1127.
- Doukhi, D., Siguret, V., Vodovar, D., Delrue, M., Reiner, P., Aghetti, A. *et al.* (2025) Cerebral venous thrombosis and nitrous oxide intoxication: Report of two cases and review of the literature. Brain Behav 15 (3) e70394, 10.1002/brb3.70394.
- Drevin, G., Gaulier, J.-M., Hakim, F., Gish, A., Férec, S., Renard, L. *et al.* (2024) Synthetic cathinones in drug-facilitated sexual assault: A case report involving the novel generation substituted cathinone N-ethylpentadron and a review of the literature. Forensic Science International 359 112030, 10.1016/j.forsciint.2024.112030.
- Drevin, G., Hahn, O., Picard, N., Baudriller, A., Renard, L., Malbranque, S. *et al.* (2025) Interest and limits of using pharmacogenetics in MDMA-related fatalities: A case report. Forensic Sci Int Genet 76 103219, 10.1016/j.fsigen.2024.103219.
- Duval, M., Rodney, M., Rousselet, M., Jaquin, C., Garot, E., Marquillier, T. *et al.* (2025). SONOPS Multicentre Cross-Sectional Study: Study of the Nitrous Oxide Perception and Use in French Dental Students. Int Dent J 75 (3) 1855-1863.
- Edeline, A., Tripault, A., Lebeau, J.P. and Pautrat, M. (2025) Cross-analyzing the opinions and experiences of nurses, physiotherapists, dentists, midwives, and pharmacists with respect to addictive disorder screening in primary care: A qualitative study. PLoS One 20 (1) e0315926, 10.1371/journal.pone.0315926.

- El Bèze, N., Hamzi, K., Henry, P., Trimaille, A., El Ouahidi, A., Zakine, C. *et al.* (2025). Machine learning to detect recent recreational drug use in intensive cardiac care units. Arch Cardiovasc Dis 118 (5) 277-286.
- Epain, M., Cartiser, N., Bevalot, F., Bottinelli, C., Chatenay, C. and Fanton, L. (2024). Alpha-methyltryptamine and 5-(2-methylaminopropyl)-benzofuran (5-MAPB) fatal co-intoxication: case report and review of literature. Int J Legal Med 138 (5) 1813-1820, 10.1007/s00414-024-03236-w.
- Fortin, D., Di Beo, V., Carrieri, P. and Barré, T. (2025). Therapeutic use and other reasons to consume cannabidiol: Insight from the French and Italian contexts. Journal of Psychoactive Drugs 57 (1) 110-120, 10.1080/02791072.2023.2285843.
- Frances, P., Marachian, L., Ngoyi-Mushimbe, N., Gaubert, R. and Manjaoui, S. (2025). Quelles substances psychoactives consommées par les sans-abris ? (in French only). Médecine 21 (2) 71-78, 10.1684/med.2025.1068.
- Frauger, E., Fouilhé, N., Lacroix, C., Daveluy, A., Le Boisselier, R., Bertin, C. *et al.* (2024). Augmentation des surdoses et décès en lien avec la consommation de méthadone durant la crise sanitaire liée au COVID-19 en 2020 [Increase of overdose and deaths related to methadone during COVID-19 epidemic in 2020] (with English abstract). Thérapies 79 (3) 297-306, 10.1016/j.therap.2023.06.004.
- Gérome, C. (2024). Angoisse, souffrance psychique, addictions : illustration de liens complexes (in French only). Rhizome (90-91) 22-23.
- Guerlais, M., Deheul, S., Le Boisselier, R. and Victorri-Vigneau, C. (2025). Non-medical nitrous oxide misuse: From identifying a signal to unprecedented addictovigilance network communication. Thérapies 80 (2) 223-229.
- Guyon, J., Maillot, A., Bastard, S., Weisse, F., Daveluy, A. and Mété, D. (2025). Psychoactive cocktail consumption on Reunion Island: a case report. Journal of Analytical Toxicology 49 (5) 369-373, 10.1093/jat/bkaf009.
- Hamard, J., Rousseau, V., Durrieu, G., Garcia, P., Yrondi, A., Sommet, A. *et al.* (2024) Psychosis with use of amphetamine drugs, methylphenidate and atomoxetine in adolescent and adults. BMJ Ment Health 27 (1) e300876, 10.1136/bmjment-2023-300876.
- Jagailloux, Y., Le Saos, F., Rouille, A. and Carre, J.-L. (2025). Consommation de Delta-9-tetrahydrocannabiphorol [THCP] en « space cake » : à propos d'un cas [Consumption of Delta-9-tetrahydrocannabiphorol [THCP] in "space cake": About a case] (with English abstract). Toxicologie Analytique et Clinique 37 (1) 77-81.
- Jauffret-Roustide, M. (2024). La construction du crack comme « problème public ». Socio-histoire des imaginaires sur des publics considérés comme « indésirables » (1986-2023) [The construction of crack as a "public problem." Socio-history of imaginaries on "unwanted" populations (1986-2023)] (with English abstract). Histoire, médecine et santé (26) 95-114.
- Jean, F.A.M., Moulin, F., Schwartz, A.N., Castel, L., Montagni, I., Macalli, M. *et al.* (2024). Association between ADHD symptoms and illicit stimulants use following 1 year among French university students of the i-Share cohort. Soc Psychiatry Psychiatr Epidemiol 59 (5) 887-897, 10.1007/s00127-023-02499-9.
- Kim, S., Kim, H., Kim, S., Lee, H., Hammoodi, A., Choi, Y. *et al.* (2025) Machine learning-based prediction of substance use in adolescents in three independent worldwide cohorts: Algorithm development and validation study. J Med Internet Res 27 e62805, 10.2196/62805.
- Kim, S., Lee, H., Woo, S., Lee, H., Park, J., Kim, T. *et al.* (2025) Global, regional, and national trends in drug use disorder mortality rates across 73 countries from 1990 to 2021, with projections up to

2040: a global time-series analysis and modelling study. EClinicalMedicine 79 102985, 10.1016/j.eclinm.2024.102985.

Kintz, P., Blanchot, A., Farrugia, A. and Goullé, J.-P. (2025). Aspects toxicologiques de la soumission chimique [Toxicological aspects of chemical submission] (with English abstract). La Revue du Praticien 75 (3) 316-320.

Labadie, M., Nardon, A., Castaing, N., Bragança, C., Daveluy, A., Gaulier, J.M. *et al.* (2024). Hexahydrocannabinol poisoning reported to French poison centres. Clinical Toxicology 62 (2) 112-119, 10.1080/15563650.2024.2318409.

Lacroix, C., Frauger, E., Jouve, E., Peyrière, H. and Micallef, J. (2025). Monitoring misuse and abuse of psychoactive substances in France: Insights from substance abuse treatment facilities through the OPPIDUM program. Therapies 80 (2) 177-186.

Le Du, G., Bourdeau, D., Gonzalez, T. and Lucet, C. (2024). Réflexion autour des consommations de toxiques en unité d'hospitalisation psychiatrique [Reflecting on drug use in psychiatric inpatient units] (with English abstract). Le Courrier des Addictions 26 (4) 6-9.

Lefeuvre, S., Richeval, C., Lelong, J., Venisse, N., Humbert, L. and Brunet, B. (2024). N-Ethylhexedrone: A very long and bad trip! A case series. Journal of Analytical Toxicology 48 (7) 507-513, 10.1093/jat/bkae040.

Léquipar, A., Dillinger, J.G., Bonnefoy-Cudraz, E., Albert, E., Attou, S., Auvray, S. *et al.* (2025). In-hospital outcomes following an acute coronary syndrome in patients with recent cannabis use. Arch Cardiovasc Dis 118 (3) 152-160, 10.1016/j.acvd.2024.10.321.

Luan, P.T., Pham, Q.L., Tan, D.D., Linh, N.T., Long, N.T., Oanh, K.T. *et al.* (2024). Suicide risk among young people who use drugs in Hanoi, Vietnam: Prevalence and related factors. J Paediatr Child Health 60 (11) 654-659, 10.1111/jpc.16648.

Magny, R., Divol, A., Fournié, C., Thiebot, P., Houzé, P. and Labat, L. (2025). La spectrométrie de masse à haute résolution : un outil pour le dépistage des nouveaux produits de synthèse [High-density mass spectrometry resolution: a tool for the screening of new synthetic products] (with English abstract). Revue Francophone des Laboratoires 2025 (570) 57-63.

Meltzer, J., Boucher, A., Cohen, S. and Morere, J. (2025) Accidental protonitazene intoxication: clinical management and detection of a novel opioid. BMJ Case Reports 18 (3) e261722, 10.1136/bcr-2024-261722.

Noble, F. (2024). Effets inter-/transgénérationnels de la cocaïne : une revue de la littérature [Inter-/transgenerational effects of cocaine: A review of the literature] (with English abstract). Bulletin de l'Académie Nationale de Médecine 208 (4) 466-471, 10.1016/j.banm.2023.10.007.

Pélessier-Alicot, A.-L. (2025). Le Chemsex : état actuel des connaissances [Chemsex: Current state of knowledge] (with English abstract). Toxicologie Analytique et Clinique 37 (1) 4-19.

Perino, J., Ramarosan, H., Ong, N., Lancelot, V., Bezin, J., Gilleron, V. *et al.* (2024). Psychoactive substance intoxication leading to general hospital admission in young and middle-aged people during and after the first lockdown. Therapies 79 (4) 419-428, <https://doi.org/10.1016/j.therap.2023.10.017>.

Perrin, S. (2025). Researchers' identities and their consequences for fieldwork. The methodological and scientific implications of gender, illicit practices and disclosure. Bulletin of Sociological Methodology ; Bulletin de Méthodologie Sociologique 165-166 (1-2) 9-44, 10.1177/07591063251321673.

Peyrière, H., Dampierre, A., Vallo, R., Lestienne, M., Eiden, C. and Donnadiou, H. (2025). Sex/gender differences in spontaneous reports to a French Addictovigilance centre. Archives of Women's Mental Health 28 (1) 191-195.

- Pirlot, G. (2024). L'emprise addictive [Addictive control] (with English abstract). Adolescence 42 (1) 141-152, 10.3917/ado.113.0141.
- Protiere, C., Sow, A., Estellon, V., Bureau, M., Leclercq, V., Grégoire, M. *et al.* (2024) Diversity of Chemsex Experiences among Men Who Have Sex with Men: Results from the French ANRS PaacX Study Using Q-Methodology. Arch Sex Behav, 10.1007/s10508-024-03007-z.
- Pruvot, C., Carpentier, O., Montmureau, A., Becquart, C., Fievet, C., Cottencin, O. *et al.* (2024) Chronic trophic disorders in cocaine and heroin injectors: A multicenter retrospective observational descriptive study. Annales de Dermatologie et de Vénérologie 151 (3) 103289, 10.1016/j.annder.2024.103289.
- Raffour, E.C., Durin, L., Monard, A. and Giagnorio, R. (2024). Deux cents ans d'histoire des usages et mésusages du protoxyde d'azote [Two hundred years of the use and misuse of nitrous oxide] (with English abstract). Annales Médico-psychologiques, revue psychiatrique 182 (9) 814-822.
- Ragusa, C., Pereira, B. and Balayssac, D. (2024). Study of the relationship between psychoactive substance use and pain in cancer patients and cancer survivors: A French nationwide cross-sectional study. Int J Cancer 155 (6) 1078-1090, 10.1002/ijc.35006.
- Riess, S., Chèze, M., Muckensturm, A., Klinger, N., Roussel, O. and Cirimele, V. (2024). 2-Fluorodeschloroketamine consumption: About two deaths and a case of self-mutilation. Journal of Analytical Toxicology 48 (5) 398-404, 10.1093/jat/bkae021.
- Robach, P., Trebes, G., Buisson, C., Mechin, N., Mazzarino, M., Garribba, F. *et al.* (2024). Prevalence of drug use in ultraendurance athletes. Medicine and Science in Sports and Exercise 56 (5) 828-838, 10.1249/mss.0000000000003374.
- Roldan, L., Sánchez-Gutiérrez, T., Fernández-Arias, I., Rodríguez-Toscano, E., López, G., Merchán-Naranjo, J. *et al.* (2024) Cannabis use and cognitive biases in people with first-episode psychosis and their siblings. Psychol Med 1-11, 10.1017/s0033291724001715.
- Roule, V., Singh, M., Trimaille, A., Delmas, C., Schurtz, G., Gerbaud, E. *et al.* (2025) Prevalence of recreational drug use in myocardial infarction patients without standard modifiable risk factors: Insights from a multicenter prospective cohort study. Int J Cardiol 429 133146, 10.1016/j.ijcard.2025.133146.
- Roux, P., Faye, A., Sagaon-Teyssier, L., Donadille, C., Briand Madrid, L., Carrieri, M.P. *et al.* (2025). Prevalence of stimulant use and the role of opioid agonist treatment among people who inject drugs in France: Results from the COSINUS cohort study. Drug and Alcohol Review 44 (1) 275-287, 10.1111/dar.13955.
- Selten, J.P., Di Forti, M., Quattrone, D., Jones, P.B., Jongsma, H.E., Gayer-Anderson, C. *et al.* (2024). The contribution of cannabis use to the increased psychosis risk among minority ethnic groups in Europe. Psychol Med 54 (11) 2937-2946, 10.1017/s0033291724001004.
- Taillefer de Laportalière, T., Redon, M., Roussin, A., Willemet, E., Very, E., Olivier, J. *et al.* (2025). First episode of catatonia followed by a psychotic episode related to chronic nitrous oxide use: A case report. Drug and Alcohol Review 44 (3) 908-912, 10.1111/dar.14012.
- Thevenin, M., Malmartel, A., Karila, L. and Camus Jacqmin, M. (2024). High lifetime prevalence of regular nitrous oxide use in French medical students. American Journal of Drug and Alcohol Abuse 50 (5) 682-689, 10.1080/00952990.2024.2392566.
- Thiebot, P., Magny, R., Langrand, J., Dufayet, L., Houze, P. and Labat, L. (2024). Analysis of homemade cannabis edibles by UHPLC-HRMS after standard addition method. Journal of Analytical Toxicology 48 (5) 372-379, 10.1093/jat/bkae014.

- Tibi-Lévy, Y., Serebryakova, D. and Jauffret-Roustide, M. (2024). Les usagers de drogues originaires d'Europe de l'Est à Paris. Analyse textométrique des données issues de l'enquête ANRS-Coquelicot-Russophones [People who use drugs from Eastern Europe in Paris. Textometric analysis of data from the ANRS-Coquelicot-Russophones survey] (with English abstract). Revue européenne des migrations internationales 40 (4) 143-166.
- Vallée, A. (2024) Heavy lifetime cannabis use and mortality by sex. JAMA Network Open 7 (6) e2415227, 10.1001/jamanetworkopen.2024.15227.
- Valter, R., Campos, C., Geoffroy, P.A., Tedgui, I., Tenenbaum, A., Lejoyeux, M. *et al.* (2024). Factors associated with changes in alcohol use among medical students during the COVID-19 pandemic. Journal of Substance Use 29 (6) 1085-1093, 10.1080/14659891.2023.2248254.
- Valter, R., Le Nézet, O., Obradovic, I., Spilka, S., Falissard, B., Josseran, L. *et al.* (2025) Cannabis and mental health in adolescents: changes in associations over 15 years. Social Psychiatry and Psychiatric Epidemiology, 10.1007/s00127-025-02859-7.
- Velter, A. and Roux, P. (2024). La pratique du chemsex dans les enquêtes nationales Rapport au sexe [ERAS] auprès des hommes ayant des rapports sexuels avec des hommes : évolutions entre 2017 et 2023 [Chemsex practice in national surveys in France on relationships to sex among men who have sex with men: Developments between 2017 and 2023] (with English abstract). Psychotropes 30 (2-3) 53-73.
- Victorri-Vigneau, C., Guerlais, M., Jaulin, E., Fan, Laforgue, E.J. and Pistorius, M.A. (2024) Thromboembolic complications following recreational use of nitrous oxide: A French Addictovigilance alert. Thromb Res 241 109096, 10.1016/j.thromres.2024.109096.
- Wallez, S., Kousignian, I., Hecker, I., Rezag Bara, S.F., Andersen, A.J., Melchior, M. *et al.* (2024) Factors associated with the use of cannabis for self-medication by adults: data from the French TEMPO cohort study. Journal of Cannabis Research 6 19, 10.1186/s42238-024-00230-2.
- Waters, M.L., Dargan, P.I., Yates, C., Dines, A.M., Eyer, F., Giraudon, I. *et al.* (2024). Clinical effects of cannabis compared to synthetic cannabinoid receptor agonists (SCRAs): a retrospective cohort study of presentations with acute toxicity to European hospitals between 2013 and 2020. Clinical Toxicology 62 (6) 378-384, 10.1080/15563650.2024.2346125.
- Weng, Y., Kruschwitz, J., Rueda-Delgado, L.M., Ruddy, K.L., Boyle, R., Franzen, L. *et al.* (2024) A robust brain network for sustained attention from adolescence to adulthood that predicts later substance use. Elife 13, 10.7554/eLife.97150.
- Willeman, T., Grunwald, J., Manceau, M., Lapierre, F., Krebs-Drouot, L., Boudin, C. *et al.* (2024) Smartphone swabs as an emerging tool for toxicology testing: a proof-of-concept study in a nightclub. Clin Chem Lab Med, 10.1515/ccim-2024-0242.
- Willeman, T., Laudet, M., Revol, B., Boudin, C., Eysseric-Guerin, H., Scolan, V. *et al.* (2025) Underreporting of synthetic cathinone poisoning with clinical immunoassays: An experimental and observational study. Annals of Clinical Biochemistry, 10.1177/00045632251331404.

**(3) Demand reduction (including prevention, treatment, harm reduction, reintegration and clinical treatment research) = 71 articles**

- Aboikoni, A., Wallyn, M., Bonifay, T., Chhorn, P., Sylla, B., Alogo, A.N.M. *et al.* (2025) Digestive endoscopic removal of cocaine pellets: Safety evaluation. Endosc Int Open 13 a25077812, 10.1055/a-2507-7812.

- Alawoè, C., Chapet, N., Roubille, F., Peyrière, H. and Eiden, C. (2024) Narrative review of heart failure related to cocaine consumption and its therapeutic management. Journal of Clinical Medicine 13 (23) 7275, 10.3390/jcm13237275.
- Angeles-Valdez, D., Rasgado-Toledo, J., Villicaña, V., Davalos-Guzman, A., Almanza, C., Fajardo-Valdez, A. *et al.* (2024) The Mexican dataset of a repetitive transcranial magnetic stimulation clinical trial on cocaine use disorder patients: SUDMEX TMS. Sci Data 11 408, 10.1038/s41597-024-03242-y.
- Aslan, A., Lessard, D. and Lebouche, B. (2024). Chemsex et sexualité. Caractériser les facteurs de vulnérabilité, les besoins des patients et les approches sexologiques lors d'une intervention en milieu hospitalier [Chemsex and sexuality: Characterizing vulnerability factors, patients' needs and sexological approaches during a hospital intervention] (with English abstract). Psychotropes 30 (2-3) 85-113, 10.3917/psyt.302.0085.
- Auriacombe, M., Alexandre, J.M., Le Tirant, L. and Serre, F. (2024). Buprénorphine d'action prolongée : quelles indications et attentes ? Mise en place par l'université de Bordeaux d'un observatoire national, OBAP (with English abstract). Le Courrier des Addictions 26 (3) 6-10.
- Baillet, E., Auriacombe, M., Romao, C., Garnier, H., Gauld, C., Vacher, C. *et al.* (2024) Craving changes in first 14 days of addiction treatment: an outcome predictor of 5 years substance use status? Transl Psychiatry 14 (1) 497, 10.1038/s41398-024-03193-3.
- Barré, T., Cazorla, G., Di Beo, V., Lopez, F., Radoszycki, L., Maradan, G. *et al.* (2024) Acceptability of and attitudes to the therapeutic use of cannabis and cannabidiol in people with Parkinson's disease: A French survey. Clinical Parkinsonism and Related Disorders 11 100286, 10.1016/j.prdoa.2024.100286.
- Beaulieu, M., Bertrand, K., Tremblay, J., Lemaitre, A. and Jauffret-Roustide, M. (2024). Personal strengths and resources that people use in their recovery from persistent substance use disorder. Drugs: Education, Prevention and Policy 31 (5) 570-583, 10.1080/09687637.2023.2247541.
- Bertrand, E. and Morvillers, J.M. (2025) Nurses' perceptions of patients with co-occurring psychiatric and substance use disorders in psychiatric settings: A grounded theory study. J Adv Nurs, 10.1111/jan.16748.
- Bichard, I. (2024). Une initiative thérapeutique innovante. L'exemple de la mise en place d'un parcours de soin dédié au chemsex dans le service des maladies infectieuses de l'hôpital Saint-Louis [An innovative therapeutic initiative: The implementation of a care pathway dedicated to chemsex in the infectious diseases department of Hôpital Saint-Louis] (with English abstract). Psychotropes 30 (2-3) 75-83.
- Biering, V., Bellouard, R., Martin, M., Dailly, É., Monteil-Ganière, C. and Le Carpentier, E.C. (2024) N-acetylcysteine use in a cocaine-induced liver failure: a case report. Front Toxicol 6 1502716, 10.3389/ftox.2024.1502716.
- Blanchette, M., Flores-Aranda, J., Bertrand, K., Lemaître, A., Jauffret-Roustide, M. and Goyette, M. (2024) Sexualized substance use among gbMSM: Their perspectives on their intervention needs and counsellor competencies. Journal of Substance Use and Addiction Treatment 159 209258, 10.1016/j.josat.2023.209258.
- Boulze-Launay, I., Rigaud, A., Basset, B. and Paille, F. (2024). Etat des lieux national de l'utilisation des méthodes psychothérapeutiques et des autres interventions non médicamenteuses en addictologie : Résultats (with English abstract). Alcoologie et Addictologie 44 (1) 7-18.
- Bramness, J.G., Leonhardt, M., Dom, G., Batalla, A., Florez Menéndez, G., Mann, K. *et al.* (2024). Education and training in addiction medicine and psychology across Europe: A EUFAS Survey. European Addiction Research 30 (3) 127-137, 10.1159/000531502.

- Brynte, C., Schellekens, A., Barta, C., Begeman, A.H.A., Crunelle, C.L., Daigre, C. *et al.* (2025) Treatments and Treatment Predictors in Patients With Substance Use Disorders and Comorbid Attention-Deficit/Hyperactivity Disorder: First Results From the International Naturalistic Cohort Study of ADHD and SUD (INCAS). J Clin Psychiatry 86 (1) 24m15494, 10.4088/JCP.24m15494.
- Cambonie, G., Aujogues dit Baron, L., Combes, C., Chanal, C., Mazurier, E., Toubin, R.-M. *et al.* (2024) Management of neonates exposed prenatally to opioids: Impact of a developmental care program implementation. Early Human Development 198 106132, 10.1016/j.earlhumdev.2024.106132.
- Chappard, P. and Pourchon, F. (2025) For a renewed harm reduction model. Harm Reduction Journal 22 23, 10.1186/s12954-025-01165-4.
- Cleirec, G. (2025). Accepter la contingence du monde pour mieux le naviguer. Contribution de l'éthique pratique aristotélicienne à une pensée de la réduction des risques [Accepting the contingency of the world to better navigate it. The contribution of Aristotelian practical ethics to harm reduction] (with English abstract). Psychotropes 31 (1) 43-61, 10.3917/psyt.311.0043.
- Clergue-Duval, V., Lyonnet, A., Azuar, J., Icick, R., Poireau, M., Rollet, D. *et al.* (2024). Hospitalized cocaine detoxification patients in Paris, France: Increased patient levels and changing population characteristics since 2011. Therapies 79 (6) 634-645.
- Collet, C. (2024). L'héroïne et ses rapports à l'Éros dans le champ de la psychose [Heroin and its relations to Eros in the field of psychosis] (with English abstract). Savoirs et clinique (31) 124-130, 10.3917/sc.031.0124.
- Coppel, A. and Perrin, S. (2024) Women, gender and drugs: between research and action. Harm Reduction Journal 21 200, 10.1186/s12954-024-01106-7.
- Crespin, R., Lhuillier, D. and Lutz Nale, G. (2024). De la prévention des « conduites addictives » en milieu de travail à l'approche écosystémique des usages de produits [From the prevention of 'addictive behaviour' in the workplace to an ecosystemic approach to the use of psychoactive substances] (with English abstract). Psychotropes 30 (4) 11-37, 10.3917/psyt.304.0011.
- Delorme, C. (2025). Éthique d'intervention, éthique de responsabilité [Ethics of intervention, ethics of responsibility] (with English abstract). Psychotropes 31 (1) 13-18, 10.3917/psyt.311.0013.
- Dervaux, A. and Stan, E. (2025). Prise en charge de patients ayant un trouble de la personnalité borderline par l'Équipe de liaison et de soins en addictologie [ELSA] : mission impossible ? [Management of homeless people in specialized alcoholology centres] (with English abstract). Le Courrier des Addictions 27 (1) 8-13.
- Deschenau, A. (2024). Les buprénorphines d'action prolongée ont transformé le paysage des traitements agonistes opioïdes en Australie. Quels enseignements pour la France ? (with English abstract). Le Courrier des Addictions 26 (4) 10-13.
- Deschenau, A., Malecot, M. and Underner, M. (2024). Prise en charge de l'usage combiné du tabac et du cannabis (with English abstract). Alcoologie et Addictologie 44 (2) 23-33.
- Donnadieu, H. and Ambrosino, M. (2024). Évaluation de la santé sexuelle des hommes ayant des relations sexuelles avec d'autres hommes, suivis en consultations d'addictologie à Montpellier, pour un usage du chemsex [Assessing the sexual health of men who have sex with men, attending addictology consultations in Montpellier for chemsex use] (with English abstract). Psychotropes 30 (2-3) 115-135.
- Duprat, L. (2024). Les conditions fragiles de la pluriprofessionnalité entre médecins et professionnels d'appui : le cas des microstructures médicales addictions (MSMA) [The fragile conditions of pluriprofessionalism between doctors and support professionals: the case of microstructures médicales addictions (MSMA)] (with English abstract). Sciences sociales et santé 42 (3) 5-31, 10.1684/sss.2024.0279.

- Duval, M., Aquizerate, A., Jaulin, E., Rousselet, M., Kuhn, E., Guilleminot, A. *et al.* (2024). Physicians, pharmacists and take-home naloxone: What practices? The SINFONI study. Therapies 79 (6) 623-633.
- Englander, H., Rolland, B. and Jauffret-Roustide, M. (2025) "Un attracteur de soins": Bringing people into care. Interdisciplinary health care professionals' attitudes toward opioid agonist therapy in France: A qualitative study with implications for the United States. Substance Use and Addiction Journal, 10.1177/29767342251324325.
- Enjolras, N., Ragonnet, D., Gaillard, M., Berger-Vergiat, A., Poinet, A., De Martene, B. *et al.* (2024). BREF-Addictions : un accompagnement psychoéducatif précoce pour les aidants accompagnant une personne avec un trouble addictif [BREF-Addictions: an early psycho-educational program for caregivers supporting individuals living with addictions] (with English abstract). Le Courrier des Addictions 26 (4) 14-20.
- Fabresse, N., Papias, E., Heckenroth, A., Martin, V., Allemann, D. and Roux, P. (2024) Implementation of a community-based LC-UV drug checking service: promising preliminary findings on feasibility and validity. Harm Reduction Journal 21 185, 10.1186/s12954-024-01098-4.
- Fouillen, K.J., Clément, C., Aous, E., Le Goff, D., Le Reste, J.Y. and Guillou-Landreat, M. (2025). General dental practitioners' knowledge, attitudes and practice towards psychoactive substance use screening: A systematic review. Drug and Alcohol Review 44 (2) 667-680.
- Grégoire, M. (2024). Liens entre la prise en charge, la psychothérapie et les facteurs déterminants dans les pratiques problématiques du chemsex, selon une expérience clinique [Links between treatment, psychotherapy, and determining factors in problematic chemsex practices: An analysis based on clinical experience] (with English abstract). Psychotropes 30 (2-3) 17-35.
- Jaumally-Jaulim, D. (2025). L'accompagnement à l'épreuve de l'addiction [Support in the face of addiction] (with English abstract). Rev Infirm 74 (309) 43-46.
- Joubert, C., Eck, M. and Fovet, T. (2024). Prescription des traitements agonistes opioïdes en milieu carcéral dans les Hauts-de-France : enquête auprès des professionnels réalisée entre 2019 et 2020 (with English abstract). Alcoologie et Addictologie 44 (2) 56-70.
- Jouet, E. and Las Vergnas, O. (2024). Journaux personnels en addictologie : recherche de traces lexicales du rétablissement au cours de la post cure [Personal diaries in addictology: the search for lexical traces of recovery during post treatment] (with English abstract). Alcoologie et Addictologie 44 (3) 124-142.
- Labrèze, L. (2024). Le cannabis thérapeutique en oncologie : bilan d'étape de l'expérimentation nationale pilotée par l'Agence nationale de sécurité du médicament (in French only). Douleur et Analgésie 37 (4) 199-211, 10.1684/dea.2024.0303.
- Lacroix, A., Puybaret, V., Villéger, P., Zattoni-Leroy, J., Cantaloube, S., Chevalier, C. *et al.* (2024). Predictive factors for acceptance of a long-acting opiate substitution treatment studied through social representations and internalized stigma. Therapies 79 (3) 307-317.
- Lalanne, L., Davalos, J.R., Audran, M., Hamelin, N., Chauvin, C., Briand-Madrid, L. *et al.* (2025). Medications for opioid use disorder in people who inject substances: Reflection on the potential place of morphine sulfate as substitution treatment? Results of COSINUS cohort study. Substance Use and Misuse 60 (3) 393-402.
- Le, T.A., Tran, L.M.H., Nguyen, L.H., Dam, V.A.T., Chiu, R.G., Ren, A. *et al.* (2024). Satisfaction amongst drug-dependent population with methadone maintenance treatment services, a comparison between public and private clinics: Implications for private sector engagement in the delivery of methadone maintenance programs across Vietnam. AIDS Behav 28 4127-4135, 10.1007/s10461-024-04521-w.

- Leleu, A. (2025). Les liaisons dangereuses entre morale et science : une application pratique au cas de la réduction des risques [The dangerous links between morality and science: a practical application to harm reduction] (with English abstract). Psychotropes 31 (1) 63-71, 10.3917/psyt.311.0063.
- Lemain, L., Lever, D., Therene-Mouden, C., Verdeau, R., Barais, M. and Guillou-Landreat, M. (2025). Chemsex among men having sex with men: A scoping review on management, support, and harm reduction strategies. Journal of Sex Research 6 (3) 367-377, 10.1080/00224499.2024.2377592.
- Lépine, B., Debin, M., Dassieu, L., Gimenez, L., Palmaro, A., Ponté, C. *et al.* (2024). GPs' practices when prescribing buprenorphine in primary care: A survey among the Sentinelles network. Therapies 79 (6) 646-654.
- Lindenmeyer, C. (2023). L'addiction, une figure de la pulsion de mort [Addiction, a manifestation of the death drive] (with English abstract). Corps & Psychisme (82) 137-148, 10.3917/cpsy2.080.0140.
- Maarek, R. (2024). L'entretien motivationnel en soins primaires, outil majeur de réduction des risques et des dommages [Motivational interviewing in primary care, a major risk and harm reduction tool] (with English abstract). Actualités Pharmaceutiques 63 (635) 27-29, 10.1016/j.actpha.2024.02.010.
- Mallet, B. (2025). Entre aliénation et émancipation : enjeux éthiques de la réduction des risques [Between alienation and self-determination: Ethical issues in harm reduction] (with English abstract). Psychotropes 31 (1) 73-91, 10.3917/psyt.311.0073.
- Maticic, M., Cernosa, J., Loboda, C., Tamse, J., Rigoni, R., Duffell, E. *et al.* (2024) How far are we? Assessing progress in hepatitis C response towards the WHO 2030 elimination goals by the civil society monitoring in 25 European countries, period 2020 to 2023. Harm Reduction Journal 21 203, 10.1186/s12954-024-01115-6.
- Mauries, S., Dufayet, G., Lengereau, A., Lejoyeux, M., Geoffroy, P.A. and Dupong, I. (2024) Cognitive-behavioral therapies in the management of adolescents with cannabis use disorder (CUD): A systematic review. Drug and Alcohol Dependence 260 111321, 10.1016/j.drugalcdep.2024.111321.
- Mick, G. and Douek, P. (2024). Clinical benefits and safety of medical cannabis products: A narrative review on natural extracts. Pain Ther 13 1063-1094, 10.1007/s40122-024-00643-0.
- Mutatayi, C., Morton, S. and Mabileau, F. (2025). Mieux intégrer les spécificités de genre en addictologie, une impulsion du Conseil de l'Europe [Improving gender sensitivity in addictology: impetus from the Council of Europe] (with English abstract). Santé Publique 37 (1) 131-140, 10.3917/spub.pr2.0049.
- Nègre, I. (2025). Cannabis médical : quoi de neuf ? [Medical cannabis: What is new?] (with English abstract). Douleurs : Évaluation - Diagnostic - Traitement 26 (1) 21-29.
- Pélerin, J.M., Gegout, T., Schwitzer, T., Schwan, R., Albuisson, E., Gédor, M. *et al.* (2025) Mindfulness-based relapse prevention for cannabis regular users: Finally outcomes of a randomized clinical trial. L'Encéphale, 10.1016/j.encep.2024.11.014.
- Pinhal, M., Schreck, B., Leboucher, J., Abesdris, J., Barrangou-Pouyes-Darlas, M., Eyzop, E. *et al.* (2024) Are the self-stigma and perceived stigma of patients treated with methadone or buprenorphine still a problem fifty years after the marketing authorization for opioid agonist treatment? The observational STIGMA study. Addiction Science and Clinical Practice 19 74, 10.1186/s13722-024-00506-1.
- Pitrat, B., Turpin, A., Peyret, E., Hamonniere, T., Drain, A., Maatoug, R. *et al.* (2024). Mobile app measuring sleep and behaviors: A trial in adolescents with addiction. L'Encéphale 50 (6) 590-596.

- Poireau, M., Segobin, S., Maillard, A., Clergue-Duval, V., Icick, R., Azuar, J. *et al.* (2024) Brain alterations in Cocaine Use Disorder: Does the route of use matter and does it relate to the treatment outcome? Psychiatry Res Neuroimaging 342 111830, 10.1016/j.pscychresns.2024.111830.
- Protais, C. and Milhet, M. (2025). La RdRD dans tous ses états : les pratiques d'accompagnement en CSAPA et CAARUD [Harm reduction in all its forms: support practices in CSAPA and CAARUD] (with English abstract). Psychotropes 31 (1) 19-42, 10.3917/psyt.311.0019.
- Ragonnet, D., Chappuy, M. and Rolland, B. (2024). Connaissances et opinions des soignants en matière de réduction des risques : résultats d'une enquête en centre hospitalo-universitaire (with English abstract). Alcoologie et Addictologie 44 (3) 43-53.
- Riegel, A. and Paille, F. (2024). La promesse des psychédéliques. Quelques données sur les thérapies assistées par LSD et par psilocybine dans les troubles de l'usage d'alcool (with English abstract). Alcoologie et Addictologie 44 (3) 8-23.
- Robin, S., Valmy, G. and P., C.J. (2025). L'utilisation des traitements de substitution aux opiacés d'action prolongée en milieu pénitentiaire (with English abstract). Le Courrier des Addictions 27 (1) 29-35.
- Rolland, B., Matheson, C., Kaski, A., Kosim, M., Roncero, C. and Vorspan, F. (2024). Compared implementation of the long-acting buprenorphine treatment Buvidal in four European countries. Expert Opinion on Drug Delivery 21 (5) 809-815, 10.1080/17425247.2024.2369756.
- Rollet, D., Moya, M., Azuar, J., Questel, F. and Icick, R. (2024). Sevrages GBL en milieu hospitalier : un retour d'expérience [Going through GBL withdrawal in hospital: Some case studies] (with English abstract). Psychotropes 30 (2-3) 151-168.
- Romeo, B., Kervadec, E., Fauvel, B., Strika-Bruneau, L., Amirouche, A., Bezo, A. *et al.* (2025) The intensity of the psychedelic experience is reliably associated with clinical improvements: A systematic review and meta-analysis. Neurosci Biobehav Rev 172 106086, 10.1016/j.neubiorev.2025.106086.
- Serre, F., Gauld, C., Lambert, L., Baillet, E., Beltran, V., Daulouede, J.P. *et al.* (2025). Predictors of substance use during treatment for addiction: A network analysis of ecological momentary assessment data. Addiction 120 (1) 48-58, 10.1111/add.16658.
- Stein, D.J., Vigo, D.V., Harris, M.G., Kazdin, A.E., Viana, M.C., Hwang, I. *et al.* (2025) Patterns and predictors of 12-month treatment of common anxiety, mood, and substance use disorders in the World Mental Health (WMH) surveys: treatment in the context of perceived need. Int J Ment Health Syst 19 10, 10.1186/s13033-025-00661-1.
- Stocker, A., Navarro, N., Schmitt, L., Delagnes, M., Doualle, A., Mallard, V. *et al.* (2024) Acceptability of "DIDE", a mobile application designed at facilitating care adherence of patients with substance use disorder. Addiction Science and Clinical Practice 19 72, 10.1186/s13722-024-00500-7.
- Tang, V.M., Aaronson, S., Abdelghani, M., Baeken, C., Barbour, T., Brunoni, A.R. *et al.* (2025). Assessment and Management of Concurrent Substance Use in Patients Receiving Repetitive Transcranial Magnetic Stimulation for Depressive, Obsessive-Compulsive, Psychotic, and Trauma-Related Disorders: A Delphi Consensus Study and Guideline. Am J Psychiatry 182 (5) 438-451.
- Therribout, N., Icick, R., Karsinti, E., Dereux, A., Bellivier, F., Vorspan, F. *et al.* (2025). Trouble du Déficit de l'Attention/Hyperactivité et Addictions : concepts et applications cliniques pour une meilleure prise en charge [Attention Deficit/Hyperactivity Disorder and Addictions: Concepts and clinical applications for better treatment] (with English abstract). Annales Médico-psychologiques, revue psychiatrique 183 (3) 249-258.

Tramond, V. (2025). La thérapie comportementale dialectique adaptée au trouble de l'usage des substances [Dialectical behavior therapy adapted for substance use disorder] (with English abstract). Le Courrier des Addictions 27 (1) 17-21.

Viana, M.C., Kazdin, A.E., Harris, M.G., Stein, D.J., Vigo, D.V., Hwang, I. *et al.* (2025) Barriers to 12-month treatment of common anxiety, mood, and substance use disorders in the World Mental Health (WMH) surveys. Int J Ment Health Syst 19 6, 10.1186/s13033-024-00658-2.

Zerhouni, O., Loisy, S., Bouthier, R. and Flaudias, V. (2024) Preventing new substance use behaviors in youth: evaluation of a two-year comprehensive program. Frontiers in Psychology 15 1339751, 10.3389/fpsyg.2024.1339751.

#### **(4) Supply, supply reduction and crime = 10 articles**

Bendjilali-Sabiani, J.-J., Eiden, C., Lestienne, M., Cherki, S., Gautre, D., Van den Broek, T. *et al.* (2024). Isotonitazene, a synthetic opioid from an emerging family: The nitazenes. Thérapies 79 (6) 655-658.

Brunet, B., Levée, C., Lelong, J. and Lefeuvre, S. (2024). Les poppers : usages, toxicité et détection [Poppers: Abuse, toxicity and detection] (with English abstract). Toxicologie Analytique et Clinique 36 (2) 158-165, 10.1016/j.toxac.2023.10.003.

Chouvy, P.-A. (2024) International property rights for Cannabis landraces and terroir products. The case of Moroccan Cannabis and hashish. International Journal of Drug Policy 129 104479, 10.1016/j.drugpo.2024.104479.

Delpirou, A. (2024). Suède : violence criminelle et trafic de cocaïne dans l'Europe de 2024 (in French only). Sécurité globale (38) 47-53, 10.3917/secug.242.0047.

Fauvergue, J.M. (2025). Terrorisme et trafic de drogue : Quelles évolutions ? (in French only). Cahiers de la Sécurité et de la Justice (60) 51-53.

Freeman, T.P., Beeching, E., Craft, S., Di Forti, M., Frison, G., Lindholst, C. *et al.* (2025). Applying machine learning to international drug monitoring: classifying cannabis resin collected in Europe using cannabinoid concentrations. Eur Arch Psychiatry Clin Neurosci 275 421-429, 10.1007/s00406-024-01816-w.

Gandilhon, M. (2024). Le crack à Paris : une dimension méconnue de la « mondialisation par le bas » (in French only). Sécurité globale (40) 95-103, 10.54695/secug.244.0095.

Ghehiouèche, F. and Riboulet-Zemouli, K. (2024). Amigos de la Hoja de Coca: History of a pioneering coca leaf fair-trade. Drugs, Habits and Social Policy 25 (2) 155-172, 10.1108/dhs-10-2023-0040.

Kozdeba, F. (2025). Le trafic de drogue : un business comme un autre ? (in French only). Cahiers de la Sécurité et de la Justice (60) 54-58.

Lien, N. and Feltran, G. (2025). (I)llicit chains: Some new hypotheses regarding a changing global cocaine market. Journal of Illicit Economies and Development 7 (1) 20-34, 10.31389/jied.274.

#### **(5) Drug policy (including laws, economic issues and strategies) = 6 articles**

Batisse, A., Chaouachi, L., Laviale, L., Beccera, L. and Djeddar, S. (2025). Impact des modifications de la réglementation sur les poppers et leur usage en France ; Impact of changing regulations related to poppers on its use in France (with English abstract). Alcoologie et Addictologie 45 (1) 29-35 (FR) ; 36-41 (EN).

Cases, C. and Beck, F. (2024). Addictions et inégalités sociales : une dimension importante pour les politiques publiques (with English abstract). Alcoologie et Addictologie 44 (1) 19-29.

Englander, H., Chappuy, M., Krawczyk, N., Bratberg, J., Potee, R., Jauffret-Roustide, M. *et al.* (2024) Comparing methadone policy and practice in France and the US: Implications for US policy reform. International Journal of Drug Policy 129 104487, 10.1016/j.drugpo.2024.104487.

Marchant, A. (2024). Une « épidémie de drogue » en France dans les années 1960-1980 ? [A "Drug Epidemic" in the 1960s-1980s in France?] (with English abstract). Histoire, médecine et santé (26) 73-93, 10.4000/12rik.

Nazif-Munoz, J.I., Dominguez-Cancino, K., Martinez, P. and Jauffret-Roustide, M. (2024) Uneven effects of twenty years of Chile's cannabis policy implementation in cannabis onset. International Journal of Drug Policy 127 104395, 10.1016/j.drugpo.2024.104395.

Rivera-Vélez, L. (2024). AMLO contre le cannabis : le tout-puissant veto présidentiel à la trajectoire de légalisation du cannabis au Mexique (with English abstract). Cahiers des Amériques latines (104).

#### (6) Others = 1 article

Yvorel, J.-J. (2024). Pour une histoire du cannabis [For a history of cannabis] (with English abstract). Histoire, médecine et santé (26) 149-159.

## T4. Additional information

The purpose of this section is to provide additional information important to drug-related research in your country that has not been provided elsewhere.

T4.1. **Optional.** Please describe any additional important sources of information, specific studies or information on drug-related research priorities. Where possible, please provide references and/or links.

T4.2. **Optional.** Please describe any other important aspect of drug-related research that has not been covered in the specific questions above. This may be additional information, a reference to an organisation in your country that monitors national drug-related research, the availability of a bibliography of recent studies or new areas of specific importance for your country.

## T5. Sources and methodology

The purpose of this section is to collect sources and bibliography for the information provided above, including brief descriptions of studies and their methodology where appropriate.

T5.1. Please list notable sources for the information provided above.

Ministère de la Justice, Ministère de l'Action et des Comptes publics and Ministère de l'Intérieur (2019). Plan national de lutte contre les stupéfiants. Dossier de presse du mardi 17 septembre 2019. Available: <https://www.interieur.gouv.fr/Actualites/L-actu-du-Ministere/Plan-national-de-lutte-contre-les-stupefiants> [accessed 22/05/2025].